Takeda

This study tested Takeda's dengue vaccine in 480 healthy people aged 4 to 60 in India. Participants received two doses of either the vaccine or a placebo, three months apart. The main goals were to check for side effects and measure the body's immune response to the vaccine.

This study tested a dengue vaccine in over 20,000 healthy children aged 4 to 16. The goal was to see if two doses could prevent dengue fever caused by any of the four dengue virus types. The vaccine aims to protect children from this serious mosquito-borne disease.

This study tested a dengue vaccine (TDV) in 187 healthy Japanese volunteers aged 4 to 60. Participants received two shots three months apart, and researchers checked how well the vaccine triggered an immune response against all four types of dengue virus. The goal is to see if th…

This study tested a new dengue vaccine in 30 healthy adults, some with prior dengue exposure and some without. The goal was to see how well the vaccine triggers the immune system to fight all four types of dengue virus. Researchers measured antibody levels over 12 months to check…

This study tested whether adding a drug called pevonedistat to the usual two-drug therapy (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 164 participants received either the …

This study looked at 688 people in South Korea with ulcerative colitis or Crohn's disease who were treated with Kynteles (vedolizumab) as part of their regular care. The main goal was to track side effects and see how many patients felt better after treatment. The results help do…

This study tested a new medication called TAK-279 for people with moderate-to-severe plaque psoriasis, a skin condition that causes red, scaly patches. About 693 adults took either TAK-279, an approved drug (apremilast), or a placebo for up to 61 weeks. The goal was to see if TAK…

This study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no pl…

This study tested an experimental drug called TAK-101 in 102 adults with celiac disease who were already eating gluten-free. The goal was to see if the drug could reduce the immune system's reaction to gluten and lessen symptoms. Participants received two doses of TAK-101 or a pl…

This study tested whether adding pevonedistat to standard azacitidine helps people with certain blood cancers (MDS, CMML, or low-blast AML) live longer without their disease getting worse. About 450 adults at high risk of progression took part. The goal was to see if the combinat…

This study looked at the long-term safety of the drug vedolizumab in children aged 2 to 17 with ulcerative colitis or Crohn's disease. 59 children who had already responded to the drug in an earlier study continued treatment. The main goal was to track any side effects over time.

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to see if the combination was safe and to measure how well it shrank tumors. Participants recei…

This study tested a new medicine called TAK-881 in 65 adults and children with primary immunodeficiency diseases, where the immune system cannot fight infections well. Participants received TAK-881 or a similar approved drug (HYQVIA) as a shot under the skin to see how the body p…

This study looked at whether the drug vedolizumab can help adults with moderate to severe Crohn's disease achieve complete remission—meaning fewer symptoms and less bowel inflammation—after 12 months of treatment. Researchers followed 72 participants in Canada, Italy, and Israel …

This study tested a medicine called leuprorelin in 80 children with central precocious puberty, a condition where puberty starts too early. The goal was to see if injections every 12 weeks could safely suppress hormones and pause further development. The approach aims to manage t…

This study tested a new drug combination (A+AVD) against the standard treatment (ABVD) for people with advanced Hodgkin lymphoma who had not been treated before. Over 1,300 participants took part. The goal was to see if the new combination could keep the cancer from coming back l…

This early-phase study tested the safety of adding TAK-079 to standard treatments for 50 adults newly diagnosed with multiple myeloma who were not eligible for stem cell transplant. The goal was to find the right dose and check for side effects. While the drug may help control th…

This study looked at the safety and effectiveness of azilsartan, a blood pressure medicine, in children aged 6 to 15 with hypertension. Five children took the drug once daily for up to 12 months. Doctors monitored side effects and blood pressure changes. The goal was to see how w…

This study tested two drugs, brigatinib and alectinib, in 248 people with advanced ALK-positive non-small-cell lung cancer whose cancer had worsened after initial treatment with crizotinib. Participants took one of the two drugs daily to see which better stopped tumor growth or s…

This study looked at 115 Chinese patients with hereditary angioedema (HAE) to see how well two approved drugs work in everyday medical practice. One drug, lanadelumab, is used to prevent attacks, and the other, icatibant, is used to stop attacks once they start. Researchers count…

This study tested a drug called TAK-625 in 5 Japanese children with Progressive Familial Intrahepatic Cholestasis (PFIC), a rare liver disease that causes severe, constant itching. The main goal was to see if the drug reduces itching and to check for side effects. Participants to…

This early-stage study tested a drug called mezagitamab in 17 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal was to check for side effects and see how the drug moves through the body. Participants received weekly injections for 8 week…

This study tested a drug called brentuximab vedotin in 50 adults with a rare type of blood cancer (systemic anaplastic large cell lymphoma) that had returned or not responded to at least one round of chemotherapy. The goal was to see how many patients had their tumors shrink or d…

This study followed 63 people with Gaucher disease in Japan who were either starting VPRIV for the first time or switching from another treatment. Researchers tracked side effects and checked if the drug helped improve key health measures like hemoglobin levels. The goal was to c…

This study tested a new drug called TAK-676, given alone or with pembrolizumab, in 248 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the highest dose people could tolerate without severe side effec…

This study tested a drug called TAK-625 in 7 Japanese children with Alagille Syndrome, a rare liver disease. The goal was to see if the drug could lower bile acid levels and reduce severe itching. Participants took the drug for up to 34 months and had regular clinic visits. Resul…

This study tested three different starting doses of the drug ponatinib in 283 people with chronic phase chronic myeloid leukemia (CML) whose cancer had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to see how well each dose r…

This study looked at the long-term side effects and effectiveness of a drug called brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma (CD30-positive cutaneous T-cell lymphoma). Participants received the drug through a vein every 3 weeks for up to 16 cycles…

This study tested whether a new daily pill, zasocitinib, works better than another pill, deucravacitinib, for people with moderate-to-severe plaque psoriasis. Over 600 adults took one of the two treatments daily for 16 weeks. The main goal was to see how many people achieved comp…

This study looked at over 1,100 people with moderate to severe ulcerative colitis who were given Entyvio (vedolizumab) as part of their regular care. The goal was to see how safe and effective the drug is over the long term. Researchers tracked side effects and how well patients …

This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and find the …

This study tested an experimental oral drug, TAK-279, in over 1,100 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, an approved psoriasis medication (apremilast), or a placebo for up to 69 weeks. The main goal was to see if TAK-279 could cle…

This study tested a drug called vedolizumab in 121 children with moderate to severe ulcerative colitis, a condition causing inflammation and pain in the gut. The goal was to see if the drug could bring about remission—meaning symptoms improve and the gut looks nearly normal on a …

This study looked at the safety of the drug Cabometyx in 263 Japanese people with a type of liver cancer called hepatocellular carcinoma. Participants took the drug as part of their normal care, and doctors watched for side effects over 12 months. The main goal was to see how oft…

This study followed 48 people with hereditary angioedema (HAE) types I and II who were treated with lanadelumab through a Polish national drug program. Researchers tracked how many patients remained free of swelling attacks over 24 months, how many attacks required rescue medicat…

This study looked at the long-term safety of a drug called TAK-771 in 15 Japanese patients with primary immunodeficiency disease (PID), a condition where the immune system is weak. Participants who completed an earlier study received TAK-771 injections for up to 3 years. The main…

This study aimed to find a better way to detect Fabry disease early by using computer programs that analyze hospital records from the last 10 years. Researchers looked at data from 50 patients to develop and test an algorithm that ranks people by how likely they are to have the d…

This study tested a new drug called TAK-861 in 105 people with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). The goal was to see if the drug improves alertness and reduces cataplexy attacks after 3 months. Participants to…

This early-stage study tested TAK-063, an experimental drug, in 77 people (some with stable schizophrenia, some healthy Japanese volunteers). The main goal was to see if the drug is safe and how the body processes it at different doses. No major claims about effectiveness were ma…

This study looked at the safety and effectiveness of the drug Firazyr (icatibant) in 32 children and teenagers (ages 2 to 17) with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Doctors gave the injection during an attack and watched for si…

This study tested whether a new drug called TAK-063 can help reduce symptoms of schizophrenia during a sudden worsening (acute exacerbation). 164 adults took either the drug or a placebo for 6 weeks. The main goal was to see if symptoms improved, measured by a standard rating sca…

This study looked at how the body handles a single injection of fazirsiran in people with different levels of liver damage (mild, moderate, or severe) compared to those with healthy livers. 34 participants received one shot and were followed for 6 months. The goal was to measure …

This study looked at the medical records of 1,477 children diagnosed with central precocious puberty (early puberty) in China. Researchers wanted to see how many received treatment and how well it worked. No new treatments were tested—the study only reviewed past data to understa…

This study observed 165 people with inflammatory bowel disease (IBD) in Poland who were taking vedolizumab either as an IV infusion or a subcutaneous injection. Researchers tracked how long patients stayed on their treatment, why some switched or stopped, and what other treatment…

This study looked at how a single dose of TAK-063 attaches to a specific brain protein (PDE10A) in 13 healthy adult men. Researchers used PET scans to measure this binding at 3 and 23 hours after taking the drug. The goal was to gather information, not to treat any disease.

This study looked at 646 people with complex fistulas caused by Crohn's disease or other conditions. Researchers observed how well standard surgeries worked in real clinics, without changing any treatments. The goal was to gather real-world evidence on healing and complications, …

This early-stage study tested a new drug called TAK-004 in 121 healthy adults to see if it is safe and how the body processes it. Participants received either TAK-004 or a placebo as an injection under the skin. The study focused on side effects, heart rate, blood pressure, and i…

This early-phase study tested the safety and how the body processes TAK-123 in 10 healthy Japanese men aged 20 to 45. Participants received a single intravenous dose, and researchers measured drug levels and side effects. The study was completed and provides basic safety data, bu…

This study looked at how the body absorbs and removes two similar medicines, TAK-881 and HyQvia, after a single injection under the skin. Thirty healthy adults aged 18 to 50 took part. The goal was to measure drug levels in the blood over 85 days, not to treat any disease.

This study looked at how often adults who already have a psychiatric condition also have undiagnosed ADHD. Researchers measured the quality of life in those diagnosed with ADHD. The goal is to raise awareness and reduce underdiagnosis.

This study looked at whether a single dose of TAK-063 can change how ketamine affects brain activity and causes psychotic-like symptoms in healthy adult men. 27 participants received TAK-063, a placebo, or ketamine in different sessions. The goal was to see if TAK-063 could preve…

This study reviewed medical records from a UK registry to understand how cytomegalovirus (CMV) infection is managed in adults after a kidney transplant. Researchers looked at data from 330 patients over 7 years to see how common refractory CMV is, what treatments are used, and ho…

This study looked back at medical records of 34 adults in the UK with von Willebrand disease (a common inherited bleeding disorder) who received a medicine called vonicog alfa (rVWF). The goal was to see how well it controlled bleeding episodes and helped during surgeries in real…

This study observed 92 adults with Crohn's disease or ulcerative colitis who were already taking or starting vedolizumab. Researchers watched whether patients chose intravenous infusions at a clinic or injections at home, and how long they stayed on their chosen treatment. The go…

This study looked at nearly 24,000 older adults (65+) with ulcerative colitis or Crohn's disease to compare infection risks from three types of advanced treatments: ENTYVIO, TNF-alpha inhibitors, and ustekinumab. Researchers used existing Medicare claims data from 2016 to 2025 to…

This study followed 354 people with ovarian cancer who were taking niraparib (Zedula) capsules daily as part of their normal care. The main goal was to watch for side effects like low blood cell counts, high blood pressure, and other serious issues over one year. Researchers did …

This study tested how well healthy adults tolerate a new medicine called TAK-881, given as an injection under the skin. 64 healthy volunteers aged 18-50 received one or more doses to check for side effects and how the body processes the drug. The goal was to see if the injection …

This study followed 482 people with multiple myeloma in China who were already taking or about to start the drug Ninlaro as part of their normal care. The goal was to collect information on side effects and how the drug is used in everyday practice, not to test a new treatment. N…